

Alfons J M Van Den Eertwegh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8232446/publications.pdf>

Version: 2024-02-01

16
papers

705
citations

840776

11
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

1177
citing authors

#	ARTICLE	IF	CITATIONS
1	Peripheral blood IFN γ -secreting $\gamma\delta$ T cell numbers are decreased in cancer patients independent of tumor type or tumor load. <i>International Journal of Cancer</i> , 2005, 116, 87-93.	5.1	201
2	Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival. <i>Clinical Cancer Research</i> , 2008, 14, 5884-5892.	7.0	127
3	Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 4532-4542.	7.0	114
4	Selective tumor antigen vaccine delivery to human CD169 antigen-presenting cells using ganglioside-liposomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 27528-27539.	7.1	54
5	Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review. <i>European Urology</i> , 2016, 70, 416-426.	1.9	51
6	New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 271-279.	1.9	34
7	CD169 Defines Activated CD14+ Monocytes With Enhanced CD8+ T Cell Activation Capacity. <i>Frontiers in Immunology</i> , 2021, 12, 697840.	4.8	33
8	Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T cell reduction and effector T cell activation. <i>Science Immunology</i> , 2022, 7, .	11.9	18
9	A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1319-1327.	6.4	15
10	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. <i>Cancers</i> , 2020, 12, 1003.	3.7	15
11	Autologous tumor cell vaccination combined with systemic CpG-B and IFN γ promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1025-1035.	4.2	13
12	Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. <i>Oncolmmunology</i> , 2016, 5, e1105431.	4.6	11
13	Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer. <i>EJNMMI Research</i> , 2019, 9, 70.	2.5	10
14	In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma. <i>Oncolmmunology</i> , 2020, 9, 1708066.	4.6	5
15	Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 43-52.	1.9	3
16	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2021, 7, 788-796.	3.1	1